

# Analysis of the changes in the management of preterm newborns born in a Spanish third-level hospital in the past 10 years

María Santiago-Souto<sup>1</sup>, Rafael García-Mozo<sup>2</sup>, and Marta Costa-Romero<sup>2,3\*</sup>

<sup>1</sup>Medicina de Familia y Comunitaria, Hospital Universitario de Cabueñes, Gijón; <sup>2</sup>Unidad de Cuidados Intensivos Neonatales, Hospital Universitario de Cabueñes, Gijón; <sup>3</sup>Departamento de Medicina, Universidad de Oviedo. Asturias, Spain

## Abstract

**Background:** Preterm newborns require the use of the best and most current strategies to treat and prevent both acute pathology and associated sequelae. This study aimed to compare the differences in the management of preterm newborns over 10 years in a tertiary hospital in Spain and its impact on height, weight, and neurological development in the medium term. **Methods:** We conducted a retrospective, observational, and analytical study examining the management and clinical variables in preterm newborns under 32 weeks of gestational age who were born in our hospital in 2011 and 2021. **Results:** Twenty-six newborns were included in the study. Significant differences in magnesium sulfate use, continuous positive airway pressure immediately after birth, and non-invasive mechanical ventilation during hospitalization were observed. Differences were found in the use of parenteral nutrition and the timing of initiation of enteral feeding. We did not observe differences in the neurological or weight evolution in the medium term. **Conclusions:** Significant differences in managing preterm newborns in these 10 years were observed. Lower mortality and alterations in central nervous system ultrasound and, significantly, less growth retardation during admission in 2021 have been observed; however, it does not manifest with improvement in long-term somatometrics or neurological prognosis.

**Keywords:** Preterm newborn. Neonatology. Surfactant. Parenteral nutrition. Postnatal malnutrition.

## Análisis de los cambios en el manejo de recién nacidos prematuros nacidos en un hospital español de tercer nivel en los últimos 10 años

## Resumen

**Introducción:** La inmadurez de los recién nacidos pretérmino (RNP) requiere el empleo de las mejores y más actuales estrategias para tratar la patología aguda y prevenir sus eventuales secuelas asociadas. El objetivo planteado es comparar las diferencias en el manejo de RNP a lo largo de diez años en un hospital de tercer nivel en España y su impacto en el desarrollo neurológico y pólmero-estatural a medio plazo. **Métodos:** Estudio retrospectivo, observacional y analítico examinando variables del manejo y clínicas de todos los RNP menores de 32 semanas de edad gestacional nacidos en nuestro hospital (nivel III-A) en 2011 y en 2021. **Resultados:** Se incluyeron 26 infantes (2011: 10 niños, 2021: 16 niños). Observamos diferencias significativas en el uso prenatal de sulfato de magnesio, mayor uso de presión positiva continua en la vía aérea (CPAP) al ingreso y ventilación mecánica no invasiva durante el ingreso, retraso en el uso de surfactante, empleo de alimentación intravenosa e inicio precoz de la alimentación enteral. Existe una menor tasa de mortalidad y desnutrición postnatal en 2021. No observamos diferencias en la evolución neurológica o ponderal a medio plazo.

### \*Correspondence:

Marta Costa-Romero  
E-mail: costamarta@uniovi.es  
1665-1146/© 2023 Hospital Infantil de México Federico Gómez. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Date of reception: 29-06-2023  
Date of acceptance: 24-11-2023  
DOI: 10.24875/BMHIM.23000093

Available online: 11-03-2024  
Bol Med Hosp Infant Mex. 2024;81(1):16-22  
[www.bmhim.com](http://www.bmhim.com)

**Conclusiones:** *Existen diferencias en el manejo de los prematuros en estos 10 años con mayor ajuste a las guías nacionales e internacionales vigentes. Esto se relaciona con menor mortalidad y alteraciones en la ecografía del sistema nervioso central y, significativamente, con un menor retraso en el crecimiento durante el ingreso en 2021; no se demostró mejoría del pronóstico somatométrico o neurológico a largo plazo.*

**Palabras clave:** *Recién nacido pretérmino. Neonatología. Surfactante. Nutrición parenteral. Desnutrición postnatal.*

## Introduction

According to the World Health Organization, a preterm newborn (PNB) is born before 37 weeks of gestation<sup>1,2</sup>. Three categories are described that classify PNB based on their gestational age:

- Extreme preterm or extremely low birth weight preterm (< 1000 g): born before 28 weeks.
- Very preterm or very low birth weight preterm (< 1500 g): born between 28 and 32 weeks.
- Moderate and late preterm: born between 32 and 37 weeks.

Worldwide, an estimated 15 million neonates are born prematurely each year. Of those who survive, a significant number face lifelong cognitive, motor, or sensory disabilities<sup>2</sup>.

PNBs have pathologies inherent to their immaturity and require careful and specific management in the neonatal intensive care unit (NICU), as described in books and systematic reviews<sup>2-8</sup>. Medical advances continue to be made, some modified previous concepts, and others confirmed classical theories and approaches. [Table 1](#) shows the established recommendations in 2011 and 2021, indicating the practices followed in those years<sup>9-29</sup>.

The changes in management, improvements in the training of neonatal staff, and state-of-the-art medical equipment have led to a significant increase in the survival of preterm infants and a decrease in the prevalence of severe neurological disability<sup>30,31</sup>. However, other types of less severe neurological problems have increased, such as neuropsychological (autism spectrum disorder, attention deficit hyperactivity disorder, and conduct disorder), motor, and learning disorders. Nutritional support assessment is also relevant, as postnatal malnutrition correlates with future neurological, weight/height alterations. Mid- to long-term follow-up of preterm infants should be coordinated by a multidisciplinary team of pediatricians, rehabilitation specialists, physiotherapists, occupational therapists, and psychologists<sup>31,32</sup>.

Therefore, the present study aimed to compare the differences in the management of PNBs born in a tertiary level hospital in 2011 and 2021 and to check whether the changes made have an impact on the

neurological development and the weight/height of the children in the medium term.

## Methods

We conducted a retrospective, observational, and analytical study to examine clinical and NICU management variables of all infants born before 32 weeks of gestation in a Level III-A hospital in 2011 and 2021. Data were obtained from medical record reviews and recorded in an anonymized database designed for the study. Families were contacted at hospital visits and provided verbal consent for review of their children's records. Those who were not followed up at the hospital were contacted by telephone.

Variables were described as mean and standard deviation, median and interquartile range or percentage according to their characteristics. Statistical tests were used according to the type of variable and according to whether the variables fit the normal (Student's t-test) or non-normal (Mann-Whitney's U) distribution. The  $\chi^2$  test was used for percentage analysis. The statistical analysis program SPSS v.22 was used. Significance was considered at  $p < 0.05$ .

The diagnosis of patent ductus arteriosus (PDA) and retinopathy of prematurity (ROP) required the involvement of pediatric cardiologists and ophthalmologists, respectively, using 2011<sup>33,34</sup> and 2021<sup>35,36</sup> guidelines. The diagnosis of bronchopulmonary dysplasia was based on dependence on oxygen or mechanical ventilation at 36 weeks of age corrected, according to the 2011<sup>37</sup> and 2021<sup>38</sup> definitions.

The percentiles of the somatometric data were obtained from <http://www.webpediatria.com><sup>39</sup> and adjusted for gestational age and sex. Data on post-discharge development were obtained from examinations at the hospital outpatient clinic and the health center. The diagnosis of behavioral disorders was based on DSM-5 criteria<sup>40</sup>.

## Results

All patients born in our hospital with gestational age < 32 weeks were included in the study: 10 born in 2011

**Table 1.** Comparison of PNB management and diagnoses in 2011 and 2021

| Variable  | 2011<br>(n = 10) | 2021<br>(n = 16) | p-value               |
|---|------------------|------------------|-----------------------|
| <b>Respiratory</b>  |                  |                  |                       |
| CPAP assistance at admission n (%)                              | 5 (50%)          | 10 (62.5%)       | 0.420*                |
| Surfactant administration n (%)                                 | 8 (80%)          | 8 (50%)          | 0.218*                |
| LISA s n (%)  | 0%               | 2 (12.5%)        | 0.467 <sup>†</sup>    |
| Surfactant timing (hours of life) Mean ± SD                     | 0.66 ± 0.73 h    | 1.8 ± 1.1 h      | 0.032 <sup>‡</sup>    |
| Duration of non-invasive ventilation (days) Mean ± SD           | 5.9 ± 6.11 days  | 7.46 ± 9.82 days | 0.728 <sup>‡</sup>    |
| Median (p25-p75)  | 4 (0.5-8.75)     | 4 (0.62-9)       | 0.787 <sup>§</sup>    |
| Duration of any type of mechanical ventilation (days) Mean ± SD | 5.9 ± 6.1 days   | 16.4 ± 25.2 days | 0.452 <sup>‡</sup>    |
| Median (p25-p75)  | 6 (4-11)         | 4.1 (3-28)       | 0.783 <sup>§</sup>    |
| <b>Hemodynamic</b>  |                  |                  |                       |
| PDA n (%)   | 1 (10%)          | 3 (20%)          | 0.626 <sup>†</sup>    |
| Medical or surgical treatment of PDA n (%)                      | 0                | 1 (7.1%)         | 1 <sup>†</sup>        |
| <b>Nutrition</b>  |                  |                  |                       |
| Intravenous feeding n (%)                                       | 1 (10%)          | 15 (93.7%)       | 0.001 <sup>†</sup>    |
| Start of IV feeding   | 24 h             | 9.86 ± 7 h       | 0.073 <sup>‡</sup>    |
| Start of enteral feeding (hours of life)                        | 1.1 ± 0.56       | 2 ± 0.94         | p = 0.02 <sup>‡</sup> |
| Breastfeeding/mixed at discharge n (%)                          | 6 (75%)          | 10 (64.3%)       | 0.394 <sup>†</sup>    |
| <b>Neurological</b>   |                  |                  |                       |
| Altered cerebral ultrasound at admission n (%)                  | 4 (40%)          | 3 (18.7%)        | 0.369 <sup>†</sup>    |
| Kangaroo care n (%)   | 0                | 15 (100%)        | 0 <sup>†</sup>        |
| <b>Infectious</b>   |                  |                  |                       |
| Antibiotics at admission n (%)                                  | 9 (90%)          | 3 (18.7%)        | 0.001 <sup>†</sup>    |
| Nosocomial sepsis n (%)   | 6 (60%)          | 4 (28%)          | 0.211 <sup>†</sup>    |
| <b>Hematological</b>  |                  |                  |                       |
| EPO n (%)   | 8 (80%)          | 5 (33%)          | 0.041 <sup>†</sup>    |
| Transfusions n (%)  | 5 (50%)          | 6 (40%)          | 0.622 <sup>†</sup>    |
| <b>Ophthalmological</b>   |                  |                  |                       |
| ROP n (%)   | 0                | 1 (7.1%)         | 1 <sup>†</sup>        |
| <b>Others</b>   |                  |                  |                       |
| Umbilical vein cannulation at admission n (%)                   | 5 (50%)          | 14 (87.5%)       | 0.048 <sup>†</sup>    |
| Mortality n (%)   | 2 (20%)          | 2 (12.5%)        | 0.625 <sup>†</sup>    |

\* $\chi^2$ .

<sup>†</sup>Fisher's exact test.

<sup>‡</sup>Student's t-test.

<sup>§</sup>Mann-Whitney's U-test.

p25-p75: 25<sup>th</sup> and 75<sup>th</sup> percentile.

CPAP: continuous positive airway pressure; EPO: erythropoietin; IV: intravenous; LISA: less invasive surfactant administration; N: number; PDA: patent ductus arteriosus; PNB: premature newborn; ROP: retinopathy of prematurity; SD: standard deviation.

and 16 born in 2021. The mean gestational age was 29.05 ± 2.4 weeks, varying between 24 and 32 weeks. The surviving lowest gestational-age infants were born in 2021 (their gestational ages were 24 and 25 weeks).

Table 2 shows the epidemiologic data and prenatal management of PNBs in our hospital in 2011 and 2021. We found significant differences between both groups only in the administration of magnesium sulfate.

Regarding respiratory management, we observed fewer infants treated with surfactant and a delay in its administration in 2021 (Fig. 1). Notably, two patients received surfactant in the delivery room in 2011 but none in 2021. Five of the seven infants with conventional

mechanical ventilation in 2021 (84% of infants) were ventilated with volume control strategies, but none in 2011 (p < 0.05).



Since the breast milk bank of our Autonomous Community was inaugurated in 2017, no child born in 2011 received donated breast milk; instead, all children born in 2021, except for one patient at the expressed wish of the family, received donated breast milk during the first days of life. The analysis of weight development during admission showed no significant differences in the percentage of weight lost (14 ± 5.5% vs. 13 ± 8.2%, p = 0.72). However, we observed a higher mean percentile of weight (20.7 ± 27 vs. 6.3 ± 7.2, p = 0.081)

**Table 2.** Epidemiological data and prenatal management among premature newborns (PNBs) in 2011 and 2021

| Variable  | 2011<br>(n = 10)               | 2021<br>(n = 16)           | p-value              |
|---|--------------------------------|----------------------------|----------------------|
| Gestational age Mean ± SD (min-max)   | 25 ± 2.4 weeks (25-32)         | 29.3 ± 2.5 weeks (24-32)   | 0.505 <sup>‡</sup>   |
| Birth weight Mean ± SD (min-max)  | 1206.5 ± 257.8 g<br>(680-1490) | 1246 ± 477 g (610-2320)    | 0.783 <sup>‡</sup>   |
| Height at birth Mean ± SD (min-max)   | 38.5 ± 4.4 cm<br>(29-45)       | 37.8 ± 4.7 cm<br>(29.5-44) | 0.932 <sup>‡</sup>   |
| Cranial perimeter at birth Mean ± SD (min-max)  | 28 ± 4.7 cm<br>(23-40)         | 28 ± 4.6 cm<br>(22-41)     | 0.988 <sup>‡</sup>   |
| Gender (males)  | 90%                            | 37.5%                      | 0.014*               |
| Lung maturity   | 80%                            | 87.5%                      | 0.625*               |
| Magnesium sulfate   | 0%                             | 75%                        | < 0.005 <sup>†</sup> |
| Cesarean section  | 50%                            | 56.2%                      | 1                    |
| Intensive resuscitation at birth (orotracheal intubation, compressions and/or adrenaline) | 50%                            | 37%                        | 0.689*               |
| Apgar score at 1 min Mean ± SD  | 5.5 ± 2.4                      | 5.5 ± 2.3                  | 0.918 <sup>‡</sup>   |
| Apgar score at 5 min Mean ± SD  | 8.1 ± 1.45                     | 7.5 ± 1.9                  | 0.385 <sup>‡</sup>   |

\* $\chi^2$ .<sup>†</sup>Fisher's exact test.<sup>‡</sup>Student's t-test.

PNB: premature newborn; SD: standard deviation.

**Figure 1.** Comparison of the timing of surfactant administration (hours of life).**Figure 2.** Comparison between birth and discharge weight percentiles in 2011 and 2021.

(Fig. 2) and height ( $13 \pm 20$  vs.  $5 \pm 4.5$ ,  $p = 0.206$ ) at discharge in 2021 compared to 2011.

Table 1 shows the percentage of children who required specific treatments and had specific diagnoses each year. Two patients died in each group, representing 20% of children in 2011 and 12.5% in 2021 ( $p = 0.625$ ).

Regarding the evolution after discharge, we did not observe significant differences in weight development or a significant relationship between somatometric data at discharge from neonatology and subsequent evolution. Only six patients (27.3%) had alterations in psychomotor development (Table 3). No significant relationship was found between weight development

**Table 3.** Relationship between results of neonatal cerebral ultrasound performed during admission and neurological disorders developed by the children subsequently and age at diagnosis

| Year | Neonatal cerebral ultrasound  | Diagnosis                        | Age at diagnosis |
|------|---|----------------------------------|------------------|
| 2011 | Germinal matrix hemorrhage.   | Autism spectrum disorder Grade 2 | 18 m             |
| 2011 | Right periventricular cystic leukomalacia   | Spastic triplegic cerebral palsy | 12-15 m          |
| 2011 | Intraventricular hydrocephalus secondary to Grade III intraventricular hemorrhage and Grade II cystic leukomalacia. | Mild left hemiparesis            | 15 m             |
| 2021 | Grade II periventricular leukomalacia+ex vacuo hydrocephalus  | Spastic diplegic cerebral palsy  | 19 m             |
| 2021 | Germinal matrix hemorrhage.   | Mild global developmental delay  | 18 m             |
| 2021 | Grade II intraventricular hemorrhage  | Mild global developmental delay  | 18 m             |

Diagnoses according to DSM-5 criteria<sup>39</sup>. m: months.

at discharge and alterations in psychomotor development. However, it was observed that all children with altered psychomotor development had alterations in the central nervous system (CNS) ultrasound performed at admission.

## Discussion

The medical records of 26 neonates born at a gestational age of < 32 weeks and admitted to the NICU of our hospital (level III-A) between 2011 and 2021 were analyzed. Although the sample size is small, the analysis of the records showed the changes that have occurred in the care of preterm infants over a decade.

Although we did not find significant differences between the two groups in gestational age and somatometric data, we observed that infants of lower gestational age (24 and 25 weeks) who survived were born in 2021. These patients had a high number of complications, longer mechanical ventilation duration, and longer hospital stays. It is noteworthy the high rate of males born in 2011, when, according to data from the Spanish National Statistics Institute (*Instituto Nacional de Estadística español*), the percentage of males born that year in our Autonomous Community was similar to that of females (51.9% males vs. 48.1% females)<sup>41</sup>. The analysis of prenatal management showed only differences in the administration of magnesium sulfate, which was expected since it was not until the mid-2010s that its use became widespread in Spain following the publication of its role as a neuroprotectant<sup>42</sup>.

There are three fundamental points in which we have observed changes in the management of these patients

in our NICU that have allowed greater harmonization with international guidelines. First, we observed differences in several aspects of respiratory management, particularly in the reduced use of surfactant, a significant delay in administering the first dose, and the generalization of less invasive administration techniques such as surfactant administration<sup>16</sup>. Similarly, we observed a trend toward greater use of noninvasive ventilation, especially continuous positive airway pressure, at admission and during hospitalization, and modalities with tidal volume control in the case of invasive mechanical ventilation, both strategies in line with the latest published evidence<sup>16,43</sup>. It is noteworthy that the duration of mechanical ventilation was longer in neonates born in 2021. This is secondary to the fact that this year, there were two patients of extreme gestational age (24 and 25 weeks) who required respiratory support for 85 and 61 days, respectively.

Second, we noted the early and widespread initiation of optimized parenteral nutrition in 2021, as indicated by national and international recommendations<sup>20,22,23</sup>, in addition to the significantly earlier initiation of enteral nutrition based on breastfeeding from the milk bank. Both factors have allowed these neonates' weight and height percentiles at discharge to be higher than in 2011. However, we could not demonstrate a relationship between weight development and neurological development as has been published<sup>44</sup>.

Third, thanks to the internationally recommended rational use of antibiotics<sup>26,27</sup>, rates of empiric antibiotic therapy decreased significantly in 2021 without an increase in early mortality due to sepsis of vertical transmission or an increase in the rate of nosocomial sepsis. In this context, the reduced use of erythropoietin, as

recommended<sup>27,29</sup>, was also confirmed, being used only in selected patients without an increase in transfusion rates.

In contrast, we did not observe significant differences in the rates of PDA, ROP, and brain lesions, problems that are very common in the first weeks of life of extremely preterm infants<sup>6-8</sup>. As for PDA and ROP, there were more cases of both in 2021 because the youngest gestational-age infants in the study were born in that year, although their incidence was lower than that published in the literature<sup>32</sup>. The rate of brain lesions observed at each stage was also lower than other reports<sup>30,31,45-47</sup>, but has a subsequent neurological impact. Based on our results and large international series<sup>30-47</sup>, we can correlate the alteration of the neonatal cerebral ultrasound with alterations in psychomotor development during early childhood. In this sense, although the differences are not significant, the most severe pictures correspond to children born in 2011 and are characterized by severe motor problems secondary to intraventricular hemorrhage.

Finally, although not statistically significant, the mortality rate is much lower in 2021, which is consistent with review articles relating improved care to increased survival of patients, especially those with extreme gestational age<sup>45-47</sup>.

As limitations, we consider that despite including all preterm infants born in our hospital in 2011 and 2021, the total sample size was small. This fact has limited the achievement of statistical significance in some comparisons but gives more value to those comparisons that have achieved it. Although there is a decade between both years studied, the changes may need more time to be evaluated. Therefore, in subsequent studies, we will consider analyzing years that are further apart in time.

There are differences in the management of preterm infants over 10 years, with greater adherence to current national and international guidelines.

Lower mortality and fewer CNS ultrasound changes, and significantly less growth retardation were observed in neonates born in 2021; however, no improvement in long-term somatometrics or neurological prognosis were demonstrated so far.

## Ethical disclosures

**Protection of human and animal subjects.** The authors declare that no experiments were performed on humans or animals for this study.

**Confidentiality of data.** The authors declare that they have followed the protocols of their work center on the publication of patient data.

**Right to privacy and informed consent.** The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author has this document.

## Conflicts of interest

The authors declare no conflicts of interest.

## Funding

No funding.

## Acknowledgment

The authors would like to thank Dr. Teresa González Martínez for her help in reviewing medical records.

## References

1. Nacimientos Prematuros. Geneva: World Health Organization; 2018. Available from: <https://www.who.int/es/news-room/fact-sheets/detail/preterm-birth>
2. Rellán S, García de Ribera C, Aragón García M. El Recién Nacido Prematuro. Protocolos Diagnóstico Terapéuticos de la AEP: Neonatología. Madrid: Asociación Española de Pediatría; 2009. Available from: [https://www.aeped.es/sites/default/files/documentos/8\\_1.pdf](https://www.aeped.es/sites/default/files/documentos/8_1.pdf)
3. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. *N Engl J Med.* 2006;354:2112-21.
4. Sola A, Chow L, Rogido M. Retinopatía de la prematuridad y oxigenoterapia: una relación cambiante. *An Pediatr.* 2005;62:48-63.
5. Tin W, Gupta S. Optimum oxygen therapy in preterm babies. *Arch Dis Child Fetal Neonatal Ed.* 2007;92:F143-7.
6. Hennuy N, Lefebvre C, de Halleux V, Snyers D, Tribollet S, Viellevoe R, et al. Actualités thérapeutiques en néonatalogie. *Rev Med Liege.* 2020;75:415-9.
7. Mandy T. In: Shefner JM, editor. Overview of Short-term Complications in Preterm Infants. Waltham, MA: Wolters Kluwer N.V.; 2023.
8. Eichenwald EC, Stark AR. Management and outcomes of very low birth weight. *N Engl J Med.* 2008;358:1700-11.
9. Brookfield KF, Vinson A. Magnesium sulfate use for fetal neuroprotection. *Curr Opin Obstet Gynecol.* 2019;31:110-5.
10. Hernández S, Ferrero L, Palacio M. Protocolo Neuroprotección con Sulfato de Magnesio en Mujeres con Riesgo de Parto Prematuro. Protocolos Medicina Maternofetal. Barcelona: Hospital Clínic- Hospital Sant Joan de Déu- Universitat de Barcelona; 2023.
11. Kattwinkel J, Perlman JM, Aziz K, Colby C, Fairchild K, Gallagher J, et al. Part 15: neonatal resuscitation: 2010 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation.* 2010;122:S909-19.
12. Aziz K, Lee H, Escobedo MB, Hoover AV, Kamath-Rayne BD, Kapadia VS, et al. Part 5: neonatal resuscitation 2020 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation.* 2020;142:S524-50.
13. Zeballos Sarrato G, Avila-Alvarez A, Escrig Fernández R, Izquierdo Renau M, Ruiz Campillo C, Gómez Robles C, et al. Guía española de estabilización y reanimación neonatal 2021. Análisis, adaptación y consenso sobre las recomendaciones internacionales. *An Pediatr.* 2022;96:e1-145.e9.
14. Sweet D, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2010 update. *Neonatology.* 2010;97:402-17.
15. López de Heredia JG, Valls i Soler A. Síndrome de Dificultad Respiratoria. Protocolos Diagnóstico Terapéuticos de la AEP: Neonatología. Madrid: Asociación Española de Pediatría; 2008. p. 305-9.

16. Sweet DG, Carnielli V, Greisen G, Hallman M, Klebermass SK, Ozek E, et al. European consensus guidelines on the management of respiratory distress syndrome - 2019 update. *Neonatology*. 2023;120:3-23.
17. Saugstad OD, Aune D. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. *Neonatology*. 2014;105:55-63.
18. del Rosal Rabes T, Sáenz de Pipaón M, Martínez Biarge M, Dorronsoro I, Quero Jiménez J. Alimentación Parenteral, Líquidos Y Electrolitos. *Protocolos Diagnóstico Terapéuticos de la AEP: Neonatología*. Madrid: Asociación Española de Pediatría; 2008. p. 101-10.
19. Bustos Lozano G. Alimentación Enteral del Recién Nacido Pretérmino. *Protocolos Diagnóstico Terapéuticos de la AEP: Neonatología*. Madrid: Asociación Española de Pediatría; 2008. p. 59-67.
20. Eidelman AI, Schanler RJ, Johnston M, Landers S, Noble L, Szucs K, et al. Breastfeeding and the use of human milk. *Pediatrics*. 2012;129:e827-41.
21. Agostoni C, Buonocore G, Carnielli VP, De Curtis M, Darmaun D, Decsi T, et al. Enteral nutrient supply for preterm infants: commentary from the European society of paediatric gastroenterology, hepatology and nutrition committee on nutrition. *J Pediatr Gastroenterol Nutr*. 2010;50:85-91.
22. Rodríguez Martínez G, Blanco Rodríguez M. Nutrición en el recién nacido de bajo peso. *Protoc Diagn Ter Pediatr*. 2023;1:431-40.
23. Moltu SJ, Bronsky J, Embleton N, Gerasimidis K, Indrio F, Köglmeier J, et al. Nutritional management of the critically ill neonate: a position paper of the ESPGHAN committee on nutrition. *J Pediatr Gastroenterol Nutr*. 2021;73:274-89.
24. Mustelier GA, Díaz-Argüelles RC, Porto Rodríguez S. Nutrición parenteral precoz en el neonato grave. *Rev Cubana Pediatr*. 2004;76;(2). Available from: [http://scielo.sld.cu/scielo.php?script=sci\\_arttext&pid=S0034-75312004000200002&lng=es](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312004000200002&lng=es).
25. Cardetti M, Rodríguez S, Sola A. Uso (y abuso) de antibióticos en la medicina perinatal. *An Pediatr*. 2020;93:207.e1-7.
26. Jardine LA, Inglis GD, Davies MW. Prophylactic systemic antibiotics to reduce morbidity and mortality in neonates with central venous catheters. *Cochrane Database Syst Rev*. 2008;2008:CD006179.
27. Figueras Aloy J. Eritropoyetina en neonatología. *An Pediatr*. 2010;73:301-4.
28. Arca G, Carbonell-Estrany X. Anemia Neonatal. *Protocolos Diagnóstico Terapéuticos de la AEP: Neonatología*. Madrid: Asociación Española de Pediatría; 2008. p. 362-71.
29. Boix H, Sánchez-Redondo MD, Cernada M, Espinosa MG, Gonzalez Pacheco N, Martín A, et al. Recomendaciones para la transfusión de hemoderivados en neonatología. *An Pediatr*. 2022;97:60-e1-8.
30. Kidokoro H, Anderson PJ, Doyle LW, Woodward LJ, Neil JJ, Inder TE. Brain injury and altered brain growth in preterm infants: predictors and prognosis. *Pediatrics*. 2014;134:e444-53.
31. Latal B. Prediction of neurodevelopmental outcome after preterm birth. *Pediatr Neurol*. 2009;40:413-9.
32. Grupo de Seguimiento de la Sociedad Española de Neonatología. *Protocolo de Seguimiento Para el Recién Nacido Menor de 1500 g o Menor de 32 Semanas de Gestación*. Madrid: Sociedad Española de Neonatología; 2017. Available from: [https://www.seneo.es/images/site/publicaciones/libros/protocolo-seguimiento\\_recien\\_nacido\\_seneo-ok-web.pdf](https://www.seneo.es/images/site/publicaciones/libros/protocolo-seguimiento_recien_nacido_seneo-ok-web.pdf)
33. Golombek SG, Sola A, Baqueroa H, Borboneta D, Cabañasa F, Fajardo C, et al. Primer consenso clínico de SIBEN: enfoque diagnóstico y terapéutico del ductus arterioso permeable en recién nacidos pretérmino. *An Pediatr (Barc)*. 2008;69:454-81.
34. Camba F, Perapoch J, Martín N. Retinopatía de la Prematuridad. *Protocolos Diagnóstico Terapéuticos de la AEP: Neonatología*. Madrid: Asociación Española de Pediatría; 2008. p. 444-7.
35. Bhatt A. In: Shefner JM, editor. *Retinopathy of Prematurity (ROP): Risk Factors, Classification, and Screening*. Waltham, MA: Wolters Kluwer N.V.; 2023.
36. Philips JB 3<sup>rd</sup>. In: Shefner JM, editor. *Patent Ductus Arteriosus (PDA) in Preterm Infants: Management and Outcome*. Waltham, MA: Wolters Kluwer N.V.; 2023.
37. Izquierdo Macián I, López Andreu JA, Morcillo Sopena F. Displasia Broncopulmonar. *Protocolos Diagnóstico Terapéuticos de la AEP: Neonatología*. Madrid: Asociación Española de Pediatría; 2008. p. 316-34.
38. Sánchez Luna M, Moreno Hernando J, Botet Mussons F, Fernández Lorenzo JR, Herranz Carrillo G, Rite Gracia S, et al. Displasia broncopulmonar: definiciones y clasificación. *An Pediatr (Barc)*. 2013;79:262.e1-6.
39. Endocrino PED. Antropometría. Available from: <http://www.webpediatrica.com/endocrinoped/antropometria.php>
40. Asociación Americana de Psiquiatría, *Manual Diagnóstico y Estadístico de los Trastornos Mentales (DSM-5®)*. Arlington, VA: Asociación Americana de Psiquiatría; 2014. Available from: <https://www.federacioncatalanadah.org/wp-content/uploads/2018/12/dsm5-manualdiagnosticoestadisticodelostrastornosmentales-161006005112.pdf>
41. *Movimiento Natural de la Población: Nacimientos*. Madrid: Instituto Nacional de Estadística; 2016.
42. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. *Cochrane Database Syst Rev*. 2009;1:CD004661.
43. Belteki G, Morley CJ. Volume-targeted ventilation. *Clin Perinatol*. 2021;48:825-41.
44. Skinner AM, Narchi H. Preterm nutrition and neurodevelopmental outcomes. *World J Methodol*. 2021;11:278-93.
45. Loureiro B, Agut T, Boronat N, Martínez-Biarge M. Seguimiento a medio-largo plazo de los niños prematuros y sus familias en nuestro país. *An Pediatr*. 2019;91:139-41.
46. Glass HC, Costarino AT, Stayer SA, Brett CM, Cladis F, Davis PJ. Outcomes for extremely premature infants. *Anesth Analg*. 2015;120:1337-51.
47. Litt JS, Edwards EM, Lainwala S, Mercier C, Montgomery A, O'Reilly D, et al. Optimizing high-risk infant follow-up in nonresearch-based paradigms: the New England follow-up network. *Pediatr Qual Saf*. 2020;5:e287.